Back to Journals » Drug Design, Development and Therapy » Volume 7

The therapeutic efficacy of propranolol in children with recurrent primary epistaxis

Authors Bjelakovic B, Bojanovic M, Lukic S, Saranac L, Vukomanovic V, Prijic S, Zivkovic N, Randjelovic D

Received 18 December 2012

Accepted for publication 19 January 2013

Published 1 March 2013 Volume 2013:7 Pages 127—129


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Bojko Bjelakovic,1,2 Mila Bojanovic,2,3 Stevo Lukic,2,4 Ljiljana Saranac,1,2 Vladislav Vukomanovic,5,6 Sergej Prijic,5 Nikola Zivkovic,7 Dusica Randjelovic1

1Clinic of Pediatrics, Clinical Center, Nis, Serbia; 2Faculty of Medicine, University of Nis, Nis, Serbia; 3Clinic of Otorhinolaryngology, Clinical Center, Nis, Serbia; 4Clinic of Neurology, Clinical Center, Nis, Serbia; 5Mother and Child Health Institute, "Dr Vukan Cupic", Belgrade, Serbia; 6Faculty of Medicine, University of Belgrade, Serbia; 7Institute of Pathology, Faculty of Medicine, University of Nis, Nis, Serbia

Abstract: We hypothesized that some characteristics of beta-blockers, including negative inotropic, peripheral vasoconstrictor, and antiangiogenic effects, might be potentially useful in treating children with epistaxis. From June 2010 to March 2012, a total of seven children with recurrent primary epistaxis resistant to conventional management were observed at our institution. An overall effectiveness of propranolol was noted in all seven children when given a dose of 1.5–2 mg/kg/day (divided into three doses) as a second line therapy for terminating epistaxis. Based on our first experience, we believe that propranolol could be a favorable treatment option for patients with primary epistaxis.

Keywords: beta-blocker, epistaxis, children

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]